INCB 50465-313
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of P13Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
More Information
INCB 50465-304
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
